All Gossamer Bio wants is to go public and fast, but the start and end of the US government shutdown has thrown its IPO plans into disarray, prompting the San Diego-based biotech to once again shift gear.
In its hurry, the company has made some ill-timed decisions. One day before the US shutdown began (December 21), the company filed its prospectus with the SEC in a bid to go public. But the protracted?shutdown?? which essentially paralyzed the SEC?? prompted Gossamer to alter its plans. On January 23?? two days before the government opened?? the drug developer announced it was using a